We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00302991
First Posted: March 15, 2006
Last Update Posted: January 30, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
UCB Pharma
March 13, 2006
March 15, 2006
January 30, 2008
March 2006
October 2007   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00302991 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)
Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Epilepsy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
180
October 2007
October 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion Criteria:

  • Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.
  • Confirmed diagnosis of a concomitant chronic disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00302991
N01247
EPIKA
No
Not Provided
Not Provided
Study Director, UCB
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial M. Call Center +1 877 822 9493 (UCB)
UCB Pharma
January 2008